Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected]

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• Ewing sarcoma is the second most common pediatric bone cancer.
• Prognosis for metastatic or recurrent Ewing sarcoma remains poor.
• Radiologic evaluation is crucial for staging, monitoring, and assessing treatment response.

Purpose of the Study:

• To evaluate the role of FDG PET in assessing Ewing sarcoma.
• To determine if FDG PET can predict prognosis and monitor therapy response.
• To highlight the benefits and limitations of FDG PET in Ewing sarcoma management.

Main Methods:

• Review of standard imaging modalities (radiography, MR, CT, bone scintigraphy).
• Focus on Positron Emission Tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG).
• Comparison of FDG PET with conventional anatomic imaging.

Main Results:

• FDG PET provides information on biologic activity, estimating tumor grade.
• FDG PET detects disease progression or regression before anatomic imaging.
• FDG PET can potentially predict patient prognosis before and after neoadjuvant therapy.

Conclusions:

• FDG PET offers unique physiologic data for Ewing sarcoma management.
• It aids in optimizing staging, restaging, and therapy response assessment.
• FDG PET is most effective when combined with anatomic imaging like CT and MR.